Gantenerumab

Source: Wikipedia, the free encyclopedia.
Gantenerumab
Beta-amyloid (Aβ40/42)
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6496H10072N1740O2024S42
Molar mass146276.71 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Gantenerumab is a

Hoffmann-La Roche pharmaceuticals.[1][2]

Gantenerumab binds to and clears aggregated

A phase III clinical trial of gantenerumab was stopped early because of a lack of efficacy.[4] Gantenerumab was also evaluated in younger patients at high risk of developing Alzheimer's disease[5] but after five years of treatment, the drug did little to slow cognitive decline in patients.[6]

References

  1. ^ "Statement On A Nonproprietary Name Adopted By The Usan Council - Gantenerumab" (PDF). American Medical Association.
  2. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). World Health Organization. Archived from the original (PDF) on 2012-02-11.
  3. S2CID 4795458
    .
  4. .
  5. ^ Clinical trial number NCT01760005 for "Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (DIAN-TU)" at ClinicalTrials.gov
  6. ^ Kolata G (10 February 2020). "An Alzheimer's Treatment Fails: 'We Don't Have Anything Now'". The New York Times.